Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2007

Thomas Fabienne, Rochaix Philippe, Benlyazid Adil, Sarini Jérôme, Rives Michel, Lefebvre Jean Louis, Allal Ben C, Courbon Frédéric, Chatelut Etienne, Delord Jean-Pierre

Abstract excerpt

PURPOSE: To determine the safety and efficacy of erlotinib given as neoadjuvant treatment in patients with head and neck squamous cell carcinoma (HNSCC). Further objectives were to identify markers of response to erlotinib and to assess the pharmacodynamic effects of erlotinib in tumor cells. EXPERIMENTAL DESIGN: Patients with locally advanced nonmetastatic HNSCC were treated with erlotinib 150 mg daily pending...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Head and Neck Neoplasms

Share to In Situ Hybridization

Share to Neoadjuvant Therapy

Share to Pilot Projects

Share to Quinazolines

Source

Identifiers

PMID: 18056187
DOI: 10.1158/1078-0432.CCR-07-1370

Genes

CISH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.PMID 18056187Read ↗

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.Semantic proximity Read ↗

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Semantic proximity Read ↗

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.Semantic proximity Read ↗

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.Semantic proximity Read ↗

Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.Semantic proximity Read ↗

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.Semantic proximity Read ↗

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.Semantic proximity Read ↗

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.Semantic proximity Read ↗

Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.